Beyond cardiovascular outcomes, CHIP has been associated with metabolic disorders, including type 2 diabetes (T2D) and metabolic dysfunction-associated steatohepatitis (MASH), conditions in which chronic low-grade inflammation, insulin resistance (IR), and obesity exhibit key roles. This evidence concerns the gene STUB1 and obesity due to melanocortin 4 receptor deficiency.